Literature DB >> 24687772

MicroRNAs as therapeutic targets in human cancers.

Maitri Y Shah1, George A Calin.   

Abstract

MicroRNAs (miRNAs) are evolutionarily conserved, small, regulatory RNAs that negatively regulate gene expression. Extensive research in the last decade has implicated miRNAs as master regulators of cellular processes with essential role in cancer initiation, progression, and metastasis, making them promising therapeutic tools for cancer management. In this article, we will briefly review the structure, biogenesis, functions, and mechanism of action of these miRNAs, followed by a detailed analysis of the therapeutic potential of these miRNAs. We will focus on the strategies presently used for miRNA therapy; discuss their use and drawbacks; and the challenges and future directions for the development of miRNA-based therapy for human cancers.
© 2014 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24687772      PMCID: PMC4461221          DOI: 10.1002/wrna.1229

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev RNA        ISSN: 1757-7004            Impact factor:   9.957


  72 in total

1.  miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Authors:  Anna M Eiring; Jason G Harb; Paolo Neviani; Christopher Garton; Joshua J Oaks; Riccardo Spizzo; Shujun Liu; Sebastian Schwind; Ramasamy Santhanam; Christopher J Hickey; Heiko Becker; Jason C Chandler; Raul Andino; Jorge Cortes; Peter Hokland; Claudia S Huettner; Ravi Bhatia; Denis C Roy; Stephen A Liebhaber; Michael A Caligiuri; Guido Marcucci; Ramiro Garzon; Carlo M Croce; George A Calin; Danilo Perrotti
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

2.  Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing.

Authors:  Sonia Melo; Alberto Villanueva; Catia Moutinho; Veronica Davalos; Riccardo Spizzo; Cristina Ivan; Simona Rossi; Fernando Setien; Oriol Casanovas; Laia Simo-Riudalbas; Javier Carmona; Jordi Carrere; August Vidal; Alvaro Aytes; Sara Puertas; Santiago Ropero; Raghu Kalluri; Carlo M Croce; George A Calin; Manel Esteller
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

3.  Silencing of microRNA families by seed-targeting tiny LNAs.

Authors:  Susanna Obad; Camila O dos Santos; Andreas Petri; Markus Heidenblad; Oliver Broom; Cristian Ruse; Cexiong Fu; Morten Lindow; Jan Stenvang; Ellen Marie Straarup; Henrik Frydenlund Hansen; Troels Koch; Darryl Pappin; Gregory J Hannon; Sakari Kauppinen
Journal:  Nat Genet       Date:  2011-03-20       Impact factor: 38.330

Review 4.  Targeting microRNAs in cancer: rationale, strategies and challenges.

Authors:  Ramiro Garzon; Guido Marcucci; Carlo M Croce
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

5.  Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.

Authors:  Hai-Liang Zhang; Li-Feng Yang; Yao Zhu; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Yi-Ping Zhu; Yi-Jun Shen; Guo-Hai Shi; Ding-Wei Ye
Journal:  Prostate       Date:  2010-09-14       Impact factor: 4.104

6.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.

Authors:  Yunching Chen; Xiaodong Zhu; Xiaoju Zhang; Bin Liu; Leaf Huang
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

7.  OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma.

Authors:  Pedro P Medina; Mona Nolde; Frank J Slack
Journal:  Nature       Date:  2010-08-08       Impact factor: 49.962

8.  Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model.

Authors:  Li Ma; Ferenc Reinhardt; Elizabeth Pan; Jürgen Soutschek; Balkrishen Bhat; Eric G Marcusson; Julie Teruya-Feldstein; George W Bell; Robert A Weinberg
Journal:  Nat Biotechnol       Date:  2010-03-28       Impact factor: 54.908

9.  Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis.

Authors:  Hanyin Cheng; Lina Zhang; David E Cogdell; Hong Zheng; Aaron J Schetter; Matti Nykter; Curtis C Harris; Kexin Chen; Stanley R Hamilton; Wei Zhang
Journal:  PLoS One       Date:  2011-03-17       Impact factor: 3.240

10.  Regression of murine lung tumors by the let-7 microRNA.

Authors:  P Trang; P P Medina; J F Wiggins; L Ruffino; K Kelnar; M Omotola; R Homer; D Brown; A G Bader; J B Weidhaas; F J Slack
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

View more
  33 in total

Review 1.  A network-biology perspective of microRNA function and dysfunction in cancer.

Authors:  Cameron P Bracken; Hamish S Scott; Gregory J Goodall
Journal:  Nat Rev Genet       Date:  2016-10-31       Impact factor: 53.242

2.  Discovery of Nucleic Acid Binding Molecules from Combinatorial Biohybrid Nucleobase Peptide Libraries.

Authors:  Sebastian Pomplun; Zachary P Gates; Genwei Zhang; Anthony J Quartararo; Bradley L Pentelute
Journal:  J Am Chem Soc       Date:  2020-11-09       Impact factor: 15.419

Review 3.  Bioengineered non-coding RNA agent (BERA) in action.

Authors:  Zhijian Duan; Ai-Ming Yu
Journal:  Bioengineered       Date:  2016-07-14       Impact factor: 3.269

Review 4.  Nanoscale delivery systems for microRNAs in cancer therapy.

Authors:  Sanda Boca; Diana Gulei; Alina-Andreea Zimta; Anca Onaciu; Lorand Magdo; Adrian Bogdan Tigu; Calin Ionescu; Alexandru Irimie; Rares Buiga; Ioana Berindan-Neagoe
Journal:  Cell Mol Life Sci       Date:  2019-10-21       Impact factor: 9.261

5.  A Repertoire of MicroRNAs Regulates Cancer Cell Starvation by Targeting Phospholipase D in a Feedback Loop That Operates Maximally in Cancer Cells.

Authors:  Kristen Fite; Lobna Elkhadragy; Julian Gomez-Cambronero
Journal:  Mol Cell Biol       Date:  2016-01-19       Impact factor: 4.272

Review 6.  MicroRNA aberrations: An emerging field for gallbladder cancer management.

Authors:  Vishal Chandra; Jong Joo Kim; Balraj Mittal; Rajani Rai
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

7.  Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/Cyclin G1/MEF2D axis.

Authors:  Xiaoming Zhao; Ming Liu; Daotang Li
Journal:  Mol Cell Biochem       Date:  2014-12-04       Impact factor: 3.396

8.  A Macrocyclic Peptide Ligand Binds the Oncogenic MicroRNA-21 Precursor and Suppresses Dicer Processing.

Authors:  Matthew D Shortridge; Matthew J Walker; Tom Pavelitz; Yu Chen; Wen Yang; Gabriele Varani
Journal:  ACS Chem Biol       Date:  2017-05-02       Impact factor: 5.100

Review 9.  Bioengineering of noncoding RNAs for research agents and therapeutics.

Authors:  Pui Yan Ho; Ai-Ming Yu
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-01-13       Impact factor: 9.957

10.  miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7.

Authors:  Ying Ma; Xing-guo She; Ying-zi Ming; Qi-quan Wan
Journal:  Tumour Biol       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.